Literature DB >> 29217458

IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.

Hye-Youn Kim1, Huyen Trang Ha Thi1, Suntaek Hong2.   

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive malignancies and is associated with high mortality rates due to the lack of effective therapeutic targets. In this study, we demonstrated that insulin-like growth factor-II mRNA-binding protein 2 and 3 (IMP2 and IMP3) are specifically overexpressed in TNBC and cooperate to promote cell migration and invasion. Downregulation of both IMP2 and IMP3 in TNBC cells was found to produce a synergistic effect in suppressing cell invasion and invadopodia formation, whereas overexpression of IMP2 and IMP3 in luminal subtype cells enhanced epithelial-mesenchymal transition and metastasis. We also showed that IMP2 and IMP3 are direct targets of microRNA-200a (miR-200a), which is downregulated in TNBC. Conversely, IMP2 and IMP3 suppressed the transcription of miR-200a by destabilizing progesterone receptor (PR) mRNA through recruitment of the CCR4-NOT transcription complex subunit 1 (CNOT1) complex. Together, our findings suggest that IMP2 and IMP3 partially determine the characteristic phenotype and synergistically promote the metastasis of TNBC by downregulating PR. The identified IMP2/3-miR-200a-PR axis represents a novel double-negative feedback loop and serves as a new potential therapeutic target for the treatment of TNBC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IMP2/3; Metastasis; Progesterone receptor; RNA binding protein; TNBC

Mesh:

Substances:

Year:  2017        PMID: 29217458     DOI: 10.1016/j.canlet.2017.11.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  LCAT1 is an oncogenic LncRNA by stabilizing the IGF2BP2-CDC6 axis.

Authors:  Juze Yang; Xinyi Qian; Qiongzi Qiu; Lingling Xu; Meidie Pan; Jia Li; Jiayi Ren; Bingjian Lu; Ting Qiu; Enguo Chen; Kejing Ying; Honghe Zhang; Yan Lu; Pengyuan Liu
Journal:  Cell Death Dis       Date:  2022-10-18       Impact factor: 9.685

Review 2.  The Neglected Insulin: IGF-II, a Metabolic Regulator with Implications for Diabetes, Obesity, and Cancer.

Authors:  Jeff M P Holly; Kalina Biernacka; Claire M Perks
Journal:  Cells       Date:  2019-10-06       Impact factor: 6.600

3.  A proximity-labeling proteomic approach to investigate invadopodia molecular landscape in breast cancer cells.

Authors:  Sylvie Thuault; Claire Mamelonet; Joëlle Salameh; Kevin Ostacolo; Brice Chanez; Danièle Salaün; Emilie Baudelet; Stéphane Audebert; Luc Camoin; Ali Badache
Journal:  Sci Rep       Date:  2020-04-22       Impact factor: 4.379

Review 4.  IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives.

Authors:  Caterina Mancarella; Katia Scotlandi
Journal:  Front Cell Dev Biol       Date:  2020-01-15

5.  Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer.

Authors:  Chaofan He; Fuxin Huang; Kejia Zhang; Jun Wei; Ke Hu; Meng Liang
Journal:  J Ovarian Res       Date:  2021-02-07       Impact factor: 4.234

6.  Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.

Authors:  Fangchao Zheng; Feng Du; Haili Qian; Jiuda Zhao; Xue Wang; Jian Yue; Nanlin Hu; Yiran Si; Binghe Xu; Peng Yuan
Journal:  Biomark Res       Date:  2021-04-29

Review 7.  The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Authors:  Fangchao Zheng; Feng Du; Jiuda Zhao; Xue Wang; Yiran Si; Peng Jin; Haili Qian; Binghe Xu; Peng Yuan
Journal:  Biomark Res       Date:  2021-05-27

8.  Overexpression of p62/IMP2 can Promote Cell Migration in Hepatocellular Carcinoma via Activation of the Wnt/β-Catenin Pathway.

Authors:  Mengtao Xing; Pei Li; Xiao Wang; Jitian Li; Jianxiang Shi; Jiejie Qin; Xiaojun Zhang; Yangcheng Ma; Giulio Francia; Jian-Ying Zhang
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639

9.  IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.

Authors:  Xiang Zhang; Dawei Wang; Boke Liu; Xingwei Jin; Xianjin Wang; Junwei Pan; Weichao Tu; Yuan Shao
Journal:  J Exp Clin Cancer Res       Date:  2020-09-16

10.  RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.

Authors:  Meng Zhang; Senlin Zhao; Cong Tan; Yanzi Gu; Xuefeng He; Xiang Du; Dawei Li; Ping Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.